Today: 2 July 2026
Browse Category

NYSE:PFE 2 October 2025 - 5 November 2025

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine and antiviral pill. However, with the pandemic’s tide receding, Pfizer’s stock has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20sreuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billionstockanalysis.com – substantially smaller than several years ago and dwarfed by newer pharma stars. Dividend Appeal: One thing propping up investor interest in Pfizer is its generous dividend. The stock’s yield sits near 7%, far above the market averagenasdaq.com. Pfizer has increased its dividend annually for 16 consecutive yearsnasdaq.com, a sign of management’s commitment to returning cash to shareholders. This payout has become extremely attractive at today’s low share price – in fact, the yield is so high largely because the stock price has slumpednasdaq.com. Some analysts caution that the dividend could be adjusted if Pfizer undertakes large dealsnasdaq.com. However, even a hypothetical cut in half would leave a respectable ~3.5% yieldnasdaq.com. For now, income-focused investors see Pfizer
5 November 2025
··
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alonereuters.comreuters.com. The share price is now hovering in the low $70sreuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emergedprnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4reuters.com – reflecting hundreds of percent in gains for early investors. This latest surge was directly tied to major news: both Pfizer and Novo Nordisk submitted sweetened acquisition offers for Metsera on November 4, escalating their bidding warreuters.comreuters.com. Upon word that Metsera’s board favored Novo’s higher bid – and that a Delaware judge would allow the bidding contest to proceed freely, rather than blocking it at Pfizer’s request – traders piled into the stock, driving it up over 20% intradayreuters.comreuters.com. By the close, Metsera was up roughly +$12.5 on the day, around $73 per sharereuters.com, as the market began pricing in the possibility of an ~$86/share takeover by Novo or a counteroffer near that range.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings. From a chart perspective, Pfizer has clear support around the low-$20s – investors stepped in at ~$21 during 2025’s sell-offs, likely viewing the dividend yield as too attractive at those levels. On the upside, $28–$30 is a resistance zone, as rallies in 2024 and 2025 fizzled out there amid broader market weakness and company-specific news. A decisive break above $28 could signal a bullish trend change, but that may require tangible
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com. Pfizer, by contrast, has no obesity blockbuster drug of its own. In September it agreed to buy Metsera for up to $7.3 billion in order to jumpstart a presence in the roughly $150 billion obesity marketreuters.com. Its long-awaited annual results showed strong profits and a bumped-up full-year forecast, driven by cost cuts and steady core salesreuters.comreuters.com. But Pfizer immediately lost any lead when Novo swooped in.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensusreuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecastsstocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates. Encouraged by the quarter’s results, Pfizer raised its full-year 2025 earnings guidance for the second consecutive quarterreuters.com. The company now projects adjusted EPS of $3.00 to $3.15, signaling management’s growing confidence in the businessnasdaq.com. “We raised and narrowed our full-year 2025 adjusted diluted EPS guidance, underscoring confidence in our ability to deliver strong results,” stated Pfizer CFO David Denton in the earnings releasenasdaq.com. Notably, Pfizer maintained its full-year revenue forecast of $61–$64 billion, indicating that while profits are expected to improve, the top-line outlook remains unchangednasdaq.com. Wall Street’s current consensus falls in the middle of these rangesnasdaq.com, so Pfizer’s guidance essentially aligns with expectations on sales and slightly raises the earnings bar.
4 November 2025
···
Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

Stock index futures are firmly in the red before the opening bell, indicating Wall Street will give back some of Monday’s gains. S&P 500 futures are down roughly 0.9% and Nasdaq 100 futures off 1.2%, with Dow futures –0.7%seekingalpha.comseekingalpha.com. This comes after the Nasdaq Composite and S&P 500 ticked higher yesterday, buoyed by excitement over a big Amazon–OpenAI AI partnership, even as the Dow slippedeconomictimes.indiatimes.com. That optimism has proved short-lived; by early Tuesday, futures reversed as investors refocus on stretched valuations in the tech sector and worry that the AI boom may have overshot fundamentalsswissinfo.chswissinfo.ch. Analysts point to Palantir Technologies as a case in point. The data analytics firm beat earnings expectations and raised its annual revenue outlook to $4.4 billion, yet its stock sank over 4% in late tradingswissinfo.ch. Palantir’s shares had soared 150% year-to-date – closing at a record $207.18 on Monday – giving it a nosebleed price-to-sales ratio of 85, the richest in the S&P 500swissinfo.ch. “There’s been quite a lot of ‘sell-on-the-news,’ particularly for stocks which had outperformed prior to their earnings,” noted Karen Georges of Ecofi Investissements, adding that “when you have lofty valuations, it’s not surprising to see harsh market price action.”swissinfo.ch This dynamic
4 November 2025
···········
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peaksharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirationssharewise.com. By mid-2025, Pfizer traded near multi-year lows, though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 when it announced the drug pricing agreement and broader market sentiment toward pharma improved. However, renewed concerns – including a light prescription uptake for the latest COVID booster and uncertainty around Q3 earnings – saw the stock drift back to the mid-$24 range by early Novemberstatmuse.comstatmuse.com. In context, Pfizer has underperformed its peers. The NYSE Arca Pharma Index is roughly flat in 2025, whereas PFE was down ~11% year-to-date as of Augustreuters.com. Even after a Q2 earnings bump, Pfizer’s stock performance remains muted. Investors appear to be factoring in several near-term headwinds and adopting a “wait-and-see” stance on the company’s turnaround efforts. On a positive note, Pfizer’s hefty dividend has cushioned total returns, and the stock’s low betastockanalysis.com
3 November 2025
··
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor and Viagra, to its 2020 partnership with BioNTech delivering the first approved COVID-19 vaccine, Pfizer’s innovations have had global impact. Today the company employs about 81,000 people worldwide and operates 35+ manufacturing sitesxtalks.com. It was the world’s top drugmaker by sales during the pandemic boom, and even with post-COVID declines Pfizer is expected to generate ~$62 billion in revenue in 2025 – underscoring its massive scalets2.tech. Pfizer is also a mainstay for income investors, thanks to a rich dividend history. It has paid dividends for 87 consecutive yearsts2.tech. The current quarterly payout of $0.43/share yields roughly 7% at the prevailing stock price – over twice the yield of industry peers like Merck or Johnson & Johnsonts2.techts2.tech. This combination of global heft and shareholder returns makes Pfizer a closely watched stock, albeit one that’s been under pressure lately as it transitions beyond the pandemic windfall.
2 November 2025
·
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance. Notably, PFE is trading below its 200-day moving average, indicating lingering bearish momentumtrefis.com. On the upside, a decisive push above the $27–$28 level would be a bullish signal that the stock’s trend is turning. In the near term, the stock has managed to climb back above its 50-day moving averageinvesting.com, a positive sign, and appears to have technical support in the mid-$24 areachartmill.com. Chart indicators are mixed: Pfizer’s RSI sits around 48, smack in neutral territorychartmill.com, and its MACD momentum indicator is slightly negativechartmill.com. This suggests the stock is neither overbought nor oversold at current levels, but hasn’t yet gathered strong upward momentum. Traders may watch $23–$24 as a support zone – if PFE falls below that, it could retest the year’s low near $21. Conversely, $27 is key resistance – a breakout above that could open the door to the low-$30s. In summary, Pfizer’s chart is still repairing: the
1 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bidreuters.com. This move comes just days after the foundation coup at Novoreuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respondts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately denounced Novo’s counterbid as “reckless” and vowed to defend the original agreementreuters.com. Observers note Novo carefully included the contingent CVRs and claims it adhered to the “no raid” clause in its agreement with Pfizerreuters.com, so the fight may end up in arbitration if no private settlement is reached. Metsera specializes in obesity therapeutics beyond the current GLP-1 trend. Its lead drug MET-097i is designed for once-monthly dosing – potentially boosting convenience and tolerabilityreuters.com. A Phase 2b trial of MET-097i showed up to ~14.1% weight loss, results that experts have hailed as “remarkable”reuters.comts2.tech. Its second program, MET-233i, is an oral agent mimicking the hormone amylin, a different weight-control pathwayreuters.com. None of these drugs are
31 October 2025
····
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlierts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of September, Pfizer shares jumped ~15%, rallying from roughly $23.6 to about $27.2 by Oct. 1ts2.tech. This dramatic move was largely driven by two key announcements and marked one of PFE’s strongest weekly gains in years. After peaking above $27, PFE retreated slightly. By Oct. 27 it traded around $24.70ts2.tech, effectively consolidating the late-September gains. The stock was roughly flat over the prior week, reflecting a cautious “wait-and-see” mood as investors awaited quarterly results. Notably, even with the pullback, Pfizer remains well above its September lows, and the catalyst-rich news flow has kept a bid under the shares. As one market analyst put it, Pfizer’s recent moves have helped “clear the air” for the entire pharma sector by reducing uncertaintyreuters.comts2.tech.
30 October 2025
··
Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera Stock Skyrockets as Pfizer-Novo Clash in $9B Bidding War

Metsera’s share price has been on a roller-coaster amid takeover speculation. In late September, Pfizer agreed to buy Metsera for $47.50 per share in cash plus up to $22.50 in contingent paymentssec.gov. Pfizer CEO Albert Bourla said this deal “propels Pfizer into this key therapeutic area” of obesity treatmentsec.gov. Metsera CEO Whit Bernard called the deal “an excellent outcome for our shareholders” and praised the chance to “realize the promise of improved human health at scale” under Pfizer’s wingsec.gov. On Oct. 30, Novo Nordisk dramatically entered the fray with an unsolicited offer valuing Metsera at up to $9 billion. Novo’s proposal is $56.50 per share cash at signing plus up to $21.25 in contingent value rightsprnewswire.com. The Metsera board declared Novo’s bid a “Superior Company Proposal”, triggering a four-day window for Pfizer to respondprnewswire.com. Pfizer immediately denounced the move: a Pfizer press release called Novo’s bid “reckless” and warned it could “suppress competition” in obesity drugsmarkets.ft.com.
30 October 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener, the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of the company’s ambition. In recent acquisitions of non-obesity assets, he said Novo was showing a “relentless ambition to move faster, go further”ts2.tech. The Metsera bid follows a sweeping boardroom shake-up at Novo, where its largest shareholder demanded faster action in the U.S. marketreuters.com. Now Novo is doubling down, essentially offering a higher price to hijack Pfizer’s deal and expand its obesity pipeline.
30 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18% from a year priorts2.tech. It languished near the bottom of its 52-week rangets2.tech as the company faced a post-pandemic hangover: revenues from its COVID-19 vaccine and pill plummeted from $37.8B in 2022 to about $12.5B in 2024ts2.tech. Wall Street projected Pfizer’s EPS would fall by more than half from 2022 to 2025ts2.tech, reflecting this “COVID cliff” in sales and ongoing patent cliffs ahead. These factors, along with drug pricing worries, weighed heavily on investor sentiment through Q3 2025. That picture brightened suddenly as Q4 2025 began. In the final week of September, Pfizer’s stock staged a sharp rebound. PFE jumped about 15% in one week, rising from roughly $23.6 on Sept. 25 to around $27.2 by Oct. 1ts2.tech. On Sept. 30 alone, the stock spiked over 6%, then climbed further on Oct. 1 – marking one of Pfizer’s best weekly rallies in yearsts2.tech. This surge lifted shares toward the high end of their yearly rangets2.tech. The broader pharmaceutical sector also rallied in tandem, logging its biggest
27 October 2025
··
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

Friday’s broad rally sent all major U.S. indexes to fresh highs. The Dow’s 400‑point gain topped the largest single‑day jump of 2025, while the S&P 500 and Nasdaq also closed at record levelseconomictimes.indiatimes.com. Market leadership was clear: technology and semiconductor firms outperformed. For example, Advanced Micro Devices surged 6.5% and Nvidia 4.2% on Fridayeconomictimes.indiatimes.com. These gains reflect strong demand for AI and cloud computing products, as well as better-than-expected earnings in the sector. By contrast, shares of industrial and energy companies lagged. Boeing fell about 2.1% amid industry concerns, and major oil companies such as Exxon Mobil and Chevron slipped 1–2% as oil prices eased. The divergence highlights that investors are favoring growth-oriented tech firms over traditional cyclicals right now. Even consumer names like Walmart and Johnson & Johnson drifted lower by around 1%economictimes.indiatimes.com, suggesting caution about near-term demand.
24 October 2025
·············
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Before the late-September rally, Pfizer’s stock had been trading lethargically. As one analysis notes, PFE closed around $23.60 on Sept. 26, roughly flat for the year and down ~9% since January ts2.tech. Over the prior 12 months it had fallen about 18%, weighed down by fading COVID sales and patent losses ts2.tech. Its 52-week range was about $20.9–$30.4 ts2.tech, so the recent surge took it to the upper end of that range. The catalyst was clear: on Sept. 30 Trump’s administration announced the Pfizer pricing deal, and PFE instantly rallied. Shares jumped about 6–7% on that day and again on Oct. 1 ts2.tech ts2.tech. By Oct. 1 PFE closed around $27.21 – a one-week gain of ~15% ts2.tech ts2.tech. Trading volumes spiked to nearly 165 million shares on Sept. 30, underscoring heavy investor interest ts2.tech. In early October the stock has since retraced slightly, trading in the mid-$20s as of Oct. 17.
19 October 2025
·
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday at 22,679.98 points, up 117.44 points on the dayreuters.com. All three major U.S. indices posted weekly gains, even as intraday swings tested investors’ nerves. The tech-heavy Nasdaq remains within striking distance of its record high set earlier this month, and is up roughly 15–17% for the year to datets2.tech – a strong performance reflecting 2025’s bullish momentum. Volatility made a comeback in recent days. The CBOE Volatility Index, Wall Street’s “fear index,” briefly spiked to around 29, a level not seen since April, before easing back to ~20 by week’s endts2.tech. That intraday surge in volatility underscores investors’ fragile sentiment: after a long stretch of calm, markets are suddenly confronting a confluence of risks. “The market is becoming more volatile, but it’s also coming off of a very non-volatile period,” explained Michael Reynolds of Glenmede, noting that with stock valuations at full levels, any new shock can jolt marketsreuters.comreuters.com. Indeed, traders rushed into protective options this week – bets that would pay out if the VIX jumps into the 40s – reflecting rising
18 October 2025
·········
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year priorts2.tech. It traded near the bottom of its 52-week range, weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospectsts2.techts2.tech. In fact, Pfizer’s COVID-driven revenues had plummeted from $37.8 billion in 2022 to an estimated $12.5 B in 2024, creating a “COVID cliff” that halved earnings and soured the stock’s appealts2.tech. The result: Pfizer – once a market darling – became an underperformer in 2023–25, even as the broader S&P 500 rose modestly and other big pharma names held steadierts2.tech. That dour picture flipped almost overnight at the end of September. Starting Sept 28, Pfizer shares went on a tear, erasing months of malaise in a week. The stock rocketed from about $23.60 to $27+ by Oct 1ts2.tech. The biggest moves came in two bursts: Sept 30, when PFE jumped ~6.8% on the day, and Oct 1, when
6 October 2025
·
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com. Analysts are watching October closely. Goldman Sachs equity strategist John Marshall warned that the unusually strong September rally may give way to volatility: “Using history as a guide, we expect global equity volatility to increase in October,” he said webull.com webull.com, noting October is typically the year’s most eventful month. In short, strategists say October could be a “gauntlet” that tests this stock-market momentum webull.com webull.com.
2 October 2025
······
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

In early September 2025, Pfizer was trading in the mid–$20 range. After a relatively quiet first weeks of the month, the stock exploded higher at month-end. On Sept. 30, PFE closed at $25.48 after soaring ~6.8% that day investing.com. The rally continued on Oct. 1, with PFE closing at $27.21 investing.com. In total, Pfizer climbed roughly 15% in the five trading days Sept 26–Oct 1. By contrast, Pfizer had been about flat in August–September, hovering in the low $24s prior to this surge. The late-month gains reflect investor excitement over the Trump pricing deal and positive news on the pipeline. Over the past month, PFE is up about 10%. The 52-week range is approximately $20.9–$30.4 companiesmarketcap.com, so the stock is near the top of that range after the recent jump. Trading volumes were unusually high on Sept 30 and Oct 1 investing.com, underscoring heavy investor interest. Key catalyst days: Sept 30 and Oct 1 correspond to the Trump price-cut announcement and its follow-up investing.com reuters.com.
2 October 2025
···
1 … 8 9 10 11

Stock Market Today

  • Cramer Sees Moderna's Pipeline Opening Up Beyond Covid
    July 1, 2026, 7:50 PM EDT. CNBC's Jim Cramer said on Mad Money that Moderna now looks different than during the Covid rush, with a cancer pipeline and vaccines reaching outside infectious diseases. He sees many programs still years out but calls for buying pullbacks, pointing to Moderna's track to profits and new data from late-stage cancer trials-like the melanoma combo trial with Merck's Keytruda. Moderna shares have jumped almost 150% this year but still trade under pandemic highs. Cramer also mentions fresh regulatory wins, including FDA advisory backing for its flu shot and a European nod for its combined Covid-flu vaccine.
Go toTop